U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
about
AACR Cancer Progress Report 2014Desensitization: Overcoming the Immunologic Barriers to TransplantationObinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.Systematic synergy modeling: understanding drug synergy from a systems biology perspective.Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localizationXGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.Furan oxidation based cross-linking: a new approach for the study and targeting of nucleic acid and protein interactions.Achieving incompatible transplantation through desensitization: current perspectives and future directions.Ibrutinib in B lymphoid malignancies.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer TherapyA novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects.GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.
P2860
Q27346723-9A801421-5C14-4FA1-A6D6-43BEDE111220Q30397952-DDC435D0-6893-45D5-A2AB-F4B46EF4E3B7Q33416524-8CA2DD84-BBBE-4246-91A1-D24538975333Q35777950-F2BDEB4E-A95B-458E-AB83-25F1CA61CE1AQ37012630-035B3EAC-5EB7-450A-B372-C5D419E6A074Q37138970-3F6DFFF8-2443-4CBB-8618-F4C7E1269609Q37517482-FD2EBA11-2923-40A5-9D1E-BFE5F1A9D5E4Q38283828-4A408A2B-A454-4511-8E4C-D80A88F55F06Q38294713-3724C0F6-C6A6-4F06-807B-344D4E22A964Q38445336-21CB783E-C80B-4E4C-859D-A0D818237323Q38545545-E31BDD14-1EEA-43CF-8048-21F2FD3F24CAQ38803361-00DD1D15-2767-4E1D-8A07-3DEFDEE0E087Q42558833-1A004FB1-2F32-4693-AB0A-9A26F4DFA396Q42643066-35D676FA-9D05-48CC-A60A-7E44A869951CQ42660162-AAC85A24-87F2-463B-B3B3-B477A76C7775Q45761043-30E5A368-5F3C-4DCE-B97D-340DC4D9D1C1Q47387422-B5C735CF-FB1A-4728-94E3-CD431EE1515DQ49168895-1E1D760B-5971-466D-844A-12FF4FA6CC04Q55283747-0CA6CB01-C6C0-48FE-9787-D0C745A77D1B
P2860
U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@ast
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
type
label
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@ast
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
prefLabel
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@ast
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
P2093
P1476
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
P2093
Ann T Farrell
Barry W Miller
Chia-Wen Ko
Edvardas Kaminskas
Haleh Saber
Hyon-Zu Lee
Jeffry Florian
Joseph Grillo
Julie Bullock
P304
P356
10.1158/1078-0432.CCR-14-0516
P407
P577
2014-05-13T00:00:00Z